Palvella Therapeutics, Inc. (PVLA) Retained Earnings (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Retained Earnings for 12 consecutive years, with -$326.3 million as the latest value for Q3 2024.
- On a quarterly basis, Retained Earnings fell 5.13% to -$326.3 million in Q3 2024 year-over-year; TTM through Sep 2024 was -$326.3 million, a 5.13% decrease, with the full-year FY2022 number at -$290.4 million, down 12.94% from a year prior.
- Retained Earnings was -$326.3 million for Q3 2024 at Palvella Therapeutics, down from -$323.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $953000.0 in Q1 2022 to a low of -$326.3 million in Q3 2024.
- A 5-year average of -$165.1 million and a median of -$221.2 million in 2020 define the central range for Retained Earnings.
- Peak YoY movement for Retained Earnings: skyrocketed 391.24% in 2022, then crashed 235958.39% in 2024.
- Palvella Therapeutics' Retained Earnings stood at -$211.4 million in 2020, then dropped by 21.64% to -$257.1 million in 2021, then dropped by 12.94% to -$290.4 million in 2022, then dropped by 6.88% to -$310.4 million in 2023, then dropped by 5.13% to -$326.3 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Retained Earnings are -$326.3 million (Q3 2024), -$323.4 million (Q2 2024), and -$346000.0 (Q1 2024).